Immunoadsorption for connective tissue disease

Tsokos, 2011, Systemic lupus erythematosus, The New England Journal of Medicine, 365, 2110, 10.1056/NEJMra1100359 Sultan, 2003, Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems, Rheumatology (Oxford), 42, 230, 10.1093/rheumatology/keg069 Cervera, 2009, Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”, Journal of Autoimmunity, 32, 240, 10.1016/j.jaut.2009.02.008 Wilson, 1979, Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus, Arthritis and Rheumatism, 22, 458, 10.1002/art.1780220504 Pisetsky, 2010, The blood nucleome in the pathogenesis of SLE, Autoimmunity Reviews, 10, 35, 10.1016/j.autrev.2010.07.007 Gabrielli, 2009, Scleroderma, The New England Journal of Medicine, 360, 1989, 10.1056/NEJMra0806188 Servettaz, 2006, Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B), Clinical Immunology, 120, 212, 10.1016/j.clim.2006.02.006 Henault, 2006, DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients, Arthritis and Rheumatism, 54, 963, 10.1002/art.21646 Riemekasten, 2011, Involvement of functional autoantibodies against vascular receptors in systemic sclerosis, Annals of the Rheumatic Diseases, 70, 530, 10.1136/ard.2010.135772 Aringer, 2007, Mixed connective tissue disease: what is behind the curtain?, Best Practice and Research Clinical Rheumatology, 21, 1037, 10.1016/j.berh.2007.10.002 Furtado, 2002, Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients, Lupus, 11, 35, 10.1191/0961203302lu144oa Greidinger, 2006, A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen, Arthritis and Rheumatism, 54, 661, 10.1002/art.21566 Feldmann, 1976, Antibody-dependent cell-mediated cytotoxicity in selected autoimmune diseases, The Journal of Clinical Investigation, 58, 173, 10.1172/JCI108447 Ward, 2011, Conventional apheresis therapies: a review, Journal of Clinical Apheresis, 26, 230, 10.1002/jca.20302 Lewis, 1992, Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group, Journal of Clinical Apheresis, 7, 153, 10.1002/jca.2920070314 Wallace, 1998, Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis, Journal of Clinical Apheresis, 13, 163, 10.1002/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1 Aringer, 1998, Severe infections in plasmapheresis-treated systemic lupus erythematosus, Arthritis and Rheumatism, 41, 414, 10.1002/1529-0131(199803)41:3<414::AID-ART6>3.0.CO;2-N Doria, 1994, Therapy of lupus nephritis. A two-year prospective study, Annales de medecine interne, 145, 307 Gaubitz, 1998, Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus, Journal of Autoimmunity, 11, 495, 10.1006/jaut.1998.0229 Matic, 2001, Background and indications for protein A-based extracorporeal immunoadsorption, Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis, 5, 394, 10.1046/j.1526-0968.2001.00370.x Langone, 1980, Immune complex formation enhances the binding of staphylococcal protein A to immunoglobulin G, Biochemical and Biophysical Research Communications, 94, 473, 10.1016/0006-291X(80)91255-3 Ronspeck, 2003, Peptide based adsorbers for therapeutic immunoadsorption, Therapeutic Apheresis and Dialysis: Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 7, 91, 10.1046/j.1526-0968.2003.00017.x Koll, 1998, Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins, Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis, 2, 147, 10.1111/j.1744-9987.1998.tb00093.x Schneider, 1998, Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy, Kidney International Supplement, 64, S61 Schmaldienst, 2001, Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?, Rheumatology (Oxford), 40, 513, 10.1093/rheumatology/40.5.513 Stummvoll, 2009, Immunoadsorption for systemic lupus erythematosus, Atherosclerosis Supplements, 10, 110, 10.1016/S1567-5688(09)71823-9 Biesenbach, 2009, Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity, Atherosclerosis Supplements, 10, 114, 10.1016/S1567-5688(09)71824-0 Stummvoll, 2011, Immunoadsorption (IAS) for systemic lupus erythematosus, Lupus, 20, 115, 10.1177/0961203310389487 Aringer, 2012, Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland–a consensus report, Lupus, 21, 386, 10.1177/0961203311426569 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Fernandez-Nebro, 2012, Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study, Lupus, 10.1177/0961203312446627 Stummvoll, 2005, IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study, Annals of the Rheumatic Diseases, 64, 1015, 10.1136/ard.2004.029660 Stummvoll, 2004, Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy, Wiener klinische Wochenschrift, 116, 716, 10.1007/s00508-004-0232-8 Stummvoll, 2012, Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity, Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association – European Renal Association, 27, 618, 10.1093/ndt/gfr239 Daoussis, 2011, B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence, International Journal of Rheumatology, 2011, 214013, 10.1155/2011/214013 Quillinan, 2009, Disease-modifying treatment in systemic sclerosis: current status, Current Opinion in Rheumatology, 21, 636, 10.1097/BOR.0b013e3283310d57 Fukunaga, 2002, Severe dermatomyositis with rhabdomyolysis and paralytic ileus: a case successfully treated with plasmapheresis and intravenous immunoglobulin, European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies, 9, 697, 10.1046/j.1468-1331.2002.00447_10.x Seguchi, 2000, Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis, Internal Medicine, 39, 1119, 10.2169/internalmedicine.39.1119 Rech, 2006, Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease, Rheumatology (Oxford), 45, 490, 10.1093/rheumatology/kei271 Rummler, 2008, A case report of successful treatment with immunoadsorption onto protein A in mixed connective tissue disease in childhood, Therapeutic Apheresis and Dialysis: Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 12, 337, 10.1111/j.1744-9987.2008.00597.x